The Carlyle Group and Brighton Park Capital are to acquire minority stakes in Indegene, a Bangalore-headquartered enterprise healthtech solutions provider, for USD200 million.
The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company.
Founded in 1998 by five first generation entrepreneurs, Indegene has emerged as the leading digital transformation partner to the global life sciences industry.
With more than 3,000 employees across North America, Europe, China, Japan and India, Indegene provides technology platforms and commercialisation services to pharmaceutical, biotechnology, and medical device companies. Clients partner with Indegene to design, build, and manage digital-first operations that leverage data and automation to accelerate clinical development, improve regulatory compliance, enhance customer experience, and drive commercial success.
Rising competition in the global pharmaceutical market is shifting business models and driving multi-year digital transformation programs. Decisions are increasingly data-driven and leading healthcare enterprises are seeking partners with strong domain knowledge and modern technology skills as a result. Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the primary investment from Carlyle and Brighton Park to accelerate its M&A and global expansion plans.
Manish Gupta, Co-Founder and CEO of Indegene, says: “We are excited about our partnership with Carlyle and Brighton Park as their collective strengths will bring significant value to Indegene as we build on the deep domain knowledge and vertical technology we have developed over the past 20 years. Carlyle’s commitment to the healthcare sector with their global network and deep pharmaceutical expertise, coupled with Brighton Park’s deep experience in the technology sector and nuanced understanding of our space, makes the two firms the ideal partners to support our company’s continued growth.”
Neeraj Bharadwaj, Managing Director of the Carlyle Asia advisory team, says: “We have been impressed by the strong entrepreneurial energy of the management team at Indegene and their technology-led, data driven, differentiated global delivery model, as well as by their ability to scale relationships with global healthcare enterprises. We believe this puts Indegene in a strong position to benefit from the significant growth drivers we are seeing in the healthcare space. We look forward to leveraging our global healthcare network and capabilities to help the company further strengthen and expand its portfolio while deepening relationships with its global client base.”
Mark Dzialga, Managing Partner of Brighton Park Capital, says: “With a strong technology platform and a digital first approach, Indegene has established a reputation for high-quality content, analytics, and other healthcare solutions provided through a seamlessly integrated system. We have tremendous respect for Manish and the talented Indegene team, who have built the largest standalone digital transformation and commercialisation partner for healthcare enterprises globally. We are excited to partner with the company as we bring to bear our significant technology expertise to help accelerate Indegene’s global growth.”
Over the last decade, Indegene has made significant organic and inorganic investments in building a technology portfolio that caters exclusively to healthcare. This has enabled the company to grow at more than 25 per cent revenue CAGR over a decade. This growth rate is accelerating with strong industry tailwinds driving a rapid shift towards digital-first operations.
Torreya, Seyfarth Shaw, Deloitte, KPMG and Tatva Legal advised Indegene on this transaction. Moelis & Company, EY, Shardul Amarchand Mangaldas & Company, Latham & Watkins and Bain & Company acted as advisors for Carlyle. Brighton Park Capital was advised by EY, Paul Weiss and Bharucha & Partners.